187 related articles for article (PubMed ID: 1628146)
1. CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.
Xu XJ; Wiesenfeld-Hallin Z; Hughes J; Horwell DC; Hökfelt T
Br J Pharmacol; 1992 Mar; 105(3):591-6. PubMed ID: 1628146
[TBL] [Abstract][Full Text] [Related]
2. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat.
Dourish CT; O'Neill MF; Coughlan J; Kitchener SJ; Hawley D; Iversen SD
Eur J Pharmacol; 1990 Jan; 176(1):35-44. PubMed ID: 2311658
[TBL] [Abstract][Full Text] [Related]
3. The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats.
Xu XJ; Hökfelt T; Hughes J; Wiesenfeld-Hallin Z
Neuroreport; 1994 Feb; 5(6):718-20. PubMed ID: 8199346
[TBL] [Abstract][Full Text] [Related]
4. The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats.
Hoffmann O; Wiesenfeld-Hallin Z
Neuroreport; 1994 Dec; 5(18):2565-8. PubMed ID: 7696605
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin.
Panerai AE; Rovati LC; Cocco E; Sacerdote P; Mantegazza P
Brain Res; 1987 Apr; 410(1):52-60. PubMed ID: 3580899
[TBL] [Abstract][Full Text] [Related]
7. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.
Singh L; Oles RJ; Field MJ; Atwal P; Woodruff GN; Hunter JC
Br J Pharmacol; 1996 Jul; 118(5):1317-25. PubMed ID: 8818359
[TBL] [Abstract][Full Text] [Related]
8. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7105-9. PubMed ID: 1698290
[TBL] [Abstract][Full Text] [Related]
9. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.
Singh L; Field MJ; Vass CA; Hughes J; Woodruff GN
Br J Pharmacol; 1992 Jan; 105(1):8-10. PubMed ID: 1350747
[TBL] [Abstract][Full Text] [Related]
10. The selective cholecystokininB receptor antagonist L-365,260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats.
Kayser V; Idänpään-Hekkilä JJ; Christensen D; Guilbaud G
Life Sci; 1998; 62(10):947-52. PubMed ID: 9496717
[TBL] [Abstract][Full Text] [Related]
11. Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin.
Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
Neuropeptides; 1991 Jul; 19 Suppl():79-84. PubMed ID: 1715529
[TBL] [Abstract][Full Text] [Related]
12. The CCKB antagonist CI988 reduces food intake in fasted rats via a dopamine mediated pathway.
Frommelt L; Lembke V; Hofmann T; Goebel-Stengel M; Mönnikes H; Wiedenmann B; Klapp BF; Stengel A; Kobelt P
Peptides; 2013 Jan; 39():111-8. PubMed ID: 23200724
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
[TBL] [Abstract][Full Text] [Related]
14. CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze.
Wilson J; Watson WP; Little HJ
Psychopharmacology (Berl); 1998 May; 137(2):120-31. PubMed ID: 9629998
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats.
Valverde O; Roques BP
Neurosci Lett; 1998 Mar; 244(1):37-40. PubMed ID: 9578139
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
Coudoré-Civiale MA; Courteix C; Boucher M; Méen M; Fialip J; Eschalier A; Ardid D
Neurosci Lett; 2000 May; 286(1):37-40. PubMed ID: 10822147
[TBL] [Abstract][Full Text] [Related]
17. The development of morphine tolerance and dependence in rats with chronic pain.
Yu W; Hao JX; Xu XJ; Wiesenfeld-Hallin Z
Brain Res; 1997 May; 756(1-2):141-6. PubMed ID: 9187324
[TBL] [Abstract][Full Text] [Related]
18. The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCKB receptor antagonist.
Valverde O; Smadja C; Roques BP; Maldonado R
Psychopharmacology (Berl); 1997 May; 131(1):79-85. PubMed ID: 9181639
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive potentiation and attenuation of tolerance by intrathecal β-arrestin 2 small interfering RNA in rats.
Yang CH; Huang HW; Chen KH; Chen YS; Sheen-Chen SM; Lin CR
Br J Anaesth; 2011 Nov; 107(5):774-81. PubMed ID: 21926413
[TBL] [Abstract][Full Text] [Related]
20. Effects of cholecystokinin receptor agonist and antagonists on morphine dependence in mice.
Zarrindast MR; Malekzadeh A; Rezayat M; Ghazi-Khansari M
Pharmacol Toxicol; 1995 Dec; 77(6):360-4. PubMed ID: 8835359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
